J&J’s Aciphex Prescriptions May Be Feeling Effects Of Prilosec OTC Launch
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson says it is premature to determine whether sales of its prescription proton pump inhibitor Aciphex (rabeprazole 20 mg) have been negatively impacted by the September launch of Procter & Gamble's Prilosec OTC
You may also be interested in...
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market